The global Drug Discovery Market was valued at USD 71.95 billion in 2025 and is projected to reach USD 146.25 billion by 2033, growing at a CAGR of 9.29%. The U.S. market is expected to reach USD 48.97 billion by 2033. Cutting-edge technologies and increasing prevalence of diseases are driving growth.

Major players in the market include Eli Lilly, Johnson & Johnson, Pfizer, and more. Small molecules dominate the market, accounting for 59.41% share, while biologics are witnessing the fastest growth. Target Identification & Validation holds the largest market share, and High-Throughput Screening is a key technology.

North America leads the global market with a 41.27% share, while the Asia Pacific market is projected to grow at a CAGR of 9.82%. Recent developments include partnerships to accelerate drug discovery and investments in biologics research. Pfizer, Roche, and AstraZeneca are among the companies making strides in the market. The Drug Discovery Market Report offers insights on ongoing discovery programs by therapeutic area, technology adoption statistics, AI-bioinformatics integration, drug type distribution, end-user participation analytics, and technology adoption growth rate benchmarks. Stay informed on global drug discovery trends and emerging innovation hotspots. Access the complete report for in-depth analysis and outlook. Contact S&S Insider for customization or more information.

Read more at GlobeNewswire: Drug Discovery Market to Hit USD 146.25 Billion by 2033